Elsevier
Table of contents :
0.pdf……Page 1
Editor……Page 2
rad3FF38.pdf……Page 0
Honorary Editor……Page 3
Contributors……Page 4
Foreword……Page 10
Structure……Page 12
Acknowledgements……Page 13
The History of Meyler……Page 14
Classification of Adverse Drug Reactions……Page 15
Searching the online edition……Page 16
Immunologic……Page 17
References……Page 18
General Information……Page 19
Bleeding……Page 20
Immunologic……Page 21
References……Page 22
References……Page 24
Reference……Page 26
Gastrointestinal……Page 27
References……Page 28
References……Page 30
Assessing the benefit-to-harm balance of low-dose aspirin in preventing strokes and heart attacks……Page 31
Metabolism……Page 32
Gastric ulceration and hemorrhage……Page 33
Incidence……Page 34
Urinary tract……Page 36
Skin……Page 37
Tumorigenicity……Page 38
Alcohol……Page 39
Uricosuric drugs……Page 40
References……Page 41
Pregnancy……Page 45
References……Page 46
References……Page 47
References……Page 49
References……Page 50
Reference……Page 51
Heart block……Page 52
Death……Page 53
References……Page 54
Halothane……Page 57
References……Page 58
Beta3-adrenoceptor agonists……Page 59
References……Page 62
Neurocysticercosis……Page 64
Placebo-controlled studies……Page 65
Nervous system……Page 66
Antiepileptic drugs……Page 67
References……Page 68
Aluminium……Page 70
References……Page 71
Reference……Page 72
References……Page 73
General adverse effects……Page 74
Cardiovascular……Page 75
Psychological, psychiatric……Page 76
Hematologic……Page 77
Urinary tract……Page 78
Musculoskeletal……Page 79
General……Page 80
References……Page 81
References……Page 86
Ketamine……Page 88
References……Page 89
References……Page 90
Reference……Page 91
References……Page 92
References……Page 94
Renal disease……Page 96
References……Page 97
References……Page 99
References……Page 100
Gastrointestinal……Page 101
Liver……Page 102
References……Page 103
References……Page 106
Grapefruit juice……Page 107
References……Page 108
Sexual function……Page 110
References……Page 111
Nervous system……Page 113
Sensory systems……Page 114
Skin……Page 115
Musculoskeletal……Page 116
Drug overdose……Page 117
References……Page 118
Renal disease……Page 121
References……Page 122
Reference……Page 123
Death……Page 124
References……Page 125
References……Page 126
References……Page 127
References……Page 129
References……Page 130
References……Page 131
Differences between different aminoglycosides……Page 134
Animal studies……Page 135
Susceptibility factors……Page 136
Metabolism……Page 137
Susceptibility factors……Page 138
Presentation and diagnosis……Page 139
Drug resistance……Page 140
Drug dosage regimens……Page 141
Intraocular……Page 142
Penicillins……Page 143
Monitoring once-daily dosing regimens……Page 144
References……Page 145
Placebo-controlled studies……Page 153
General adverse effects……Page 154
Respiratory……Page 155
Gastrointestinal……Page 156
Urinary tract……Page 157
Lactation……Page 158
Warfarin……Page 159
References……Page 160
Studies in ventricular dysrhythmias……Page 165
Ventricular dysrhythmias……Page 166
Frequency……Page 167
Presentation……Page 168
Nervous system……Page 169
Other effects……Page 170
Hyperthyroidism……Page 171
Presentation……Page 172
Management……Page 173
Hematologic……Page 174
Pancreas……Page 175
Immunologic……Page 176
Age……Page 177
Drug administration route……Page 178
Class I antidysrhythmic drugs……Page 179
Warfarin……Page 180
References……Page 181
References……Page 189
Reference……Page 190
Ciclosporin……Page 191
References……Page 192
References……Page 193
Reference……Page 194
References……Page 195
Cardiovascular……Page 196
Stereotyped behavior……Page 197
Amphetamines and brain damage……Page 198
Phobias……Page 199
Management……Page 200
Infection risk……Page 201
Teratogenicity……Page 202
Adrenergic neuron blocking drugs……Page 203
References……Page 204
Amphotericin colloidal dispersion……Page 208
Amphotericin lipid complex……Page 209
Aerosolized amphotericin……Page 210
Amphotericin deoxycholate versus liposomal amphotericin……Page 211
Itraconazole……Page 212
Echinocandins……Page 213
Vascular effects……Page 214
Hematologic……Page 215
Mechanism……Page 216
Amphotericin B colloidal dispersion……Page 217
Prevention……Page 218
Infants……Page 219
Antifungal azoles……Page 220
References……Page 221
References……Page 227
References……Page 229
References……Page 230
References……Page 231
Psychological, psychiatric……Page 232
Liver……Page 233
Drug abuse……Page 234
Other features of the patient……Page 235
References……Page 236
General adverse effects……Page 239
References……Page 240
Use in nephropathy……Page 242
Mechanism……Page 243
Electrolyte balance……Page 244
Skin……Page 245
Fetotoxicity……Page 246
Positive studies……Page 247
Potassium supplements, potassium-sparing diuretics, or salt substitutes……Page 248
References……Page 249
Fish oils……Page 253
Kombucha ldquomushroom”,1,5,3,0,0pc,0pc,0pc,0pc……Page 254
Spanish fly……Page 255
References……Page 256
Lactation……Page 258
References……Page 259
References……Page 260
Diagnosis……Page 261
Hematologic……Page 262
Skin……Page 263
Hepatic disease……Page 264
Taxanes……Page 265
References……Page 266
Hematologic……Page 271
Skin……Page 272
References……Page 273
Hypertension……Page 275
Pharmacoeconomics……Page 276
References……Page 277
General adverse effects……Page 279
Immunologic……Page 280
References……Page 281
References……Page 282
Cardiac dysrhythmias……Page 284
Susceptibility factors……Page 285
Adverse hemodynamic effects of antidysrhythmic drugs……Page 286
References……Page 287
Hypersusceptibility reactions……Page 290
Nervous system……Page 291
Psychiatric effects……Page 292
Adrenal-pituitary axis……Page 293
Thyroid hormones……Page 294
Amino acids……Page 295
Hematologic……Page 296
Skin……Page 297
Osteoporosis……Page 298
Treatment……Page 299
Death……Page 300
Teratogenicity……Page 301
Fetotoxicity……Page 303
General……Page 304
References……Page 311
Nimorazole……Page 317
Pecilocin (Variotin)……Page 318
References……Page 319
DoTS classification……Page 321
Antihistamines and drowsiness……Page 323
Comparative studies……Page 324
Comparative studies……Page 325
Teratogenicity……Page 326
Drugs acting on the brain……Page 327
References……Page 328
Placebo-controlled studies……Page 332
Respiratory……Page 333
Immunologic……Page 334
References……Page 335
Immunologic……Page 337
Genetic factors……Page 338
Management……Page 339
References……Page 340
References……Page 342
References……Page 343
References……Page 345
References……Page 346
Teratogenicity……Page 347
References……Page 348
References……Page 350
References……Page 351
Liver……Page 352
References……Page 353
Hematologic……Page 355
References……Page 356
Artesunate+lumefantrine……Page 358
Placebo-controlled studies……Page 359
Pregnancy……Page 360
References……Page 361
References……Page 363
Immunologic……Page 364
References……Page 365
Urinary tract……Page 367
Genetic factors……Page 368
Tests for occult blood……Page 369
References……Page 370
References……Page 372
References……Page 373
Achillea millefolium……Page 376
Adverse effects……Page 377
Eupatorium species……Page 378
Tussilago farfara……Page 379
References……Page 380
References……Page 382
Atovaquone+proguanil……Page 383
References……Page 384
Temperature and pH……Page 386
Pancuronium……Page 387
References……Page 388
Drug overdose……Page 390
References……Page 391
References……Page 392
Liver……Page 393
Pancreas……Page 394
Infection risk……Page 395
Tumorigenicity……Page 396
Teratogenicity……Page 397
Genetic factors……Page 398
References……Page 399
References……Page 403
Other macrolides……Page 404
Psychological, psychiatric……Page 405
Antihistamines……Page 406
References……Page 407
BCG immunotherapy in bladder tumors……Page 410
General adverse effects of prophylactic BCG immunization……Page 411
Skin……Page 412
Immunologic……Page 413
Disseminated BCG infection……Page 414
Pregnancy……Page 415
References……Page 416
References……Page 420
Gastrointestinal……Page 421
Clinical presentation……Page 422
Fetotoxicity……Page 423
Drug overdose……Page 424
References……Page 425
References……Page 427
Immunologic……Page 428
References……Page 429
References……Page 431
References……Page 432
References……Page 433
References……Page 434
References……Page 435
References……Page 437
References……Page 438
Hematologic……Page 440
References……Page 441
Pharmacokinetics……Page 443
Pharmacodynamics……Page 444
General adverse effects……Page 445
Seizures……Page 446
Psychoses……Page 447
Teratogenicity……Page 448
Antibiotics……Page 449
Levodopa……Page 450
Tricyclic antidepressants……Page 451
References……Page 452
References……Page 457
References……Page 458
References……Page 459
References……Page 461
General Information……Page 465
Cardioselectivity……Page 467
Use in glaucoma……Page 468
Acute chest pain……Page 469
Airways obstruction……Page 470
Nervous system……Page 471
Disturbances of psychomotor function……Page 472
Hypoglycemia……Page 473
Gastrointestinal……Page 474
Skin……Page 475
Immunologic……Page 476
Fetotoxicity……Page 477
Acute myocardial infarction……Page 478
Cardiovascular……Page 479
Drug overdose……Page 480
Blood pressure……Page 481
References……Page 482
Relation to dose……Page 492
Nervous system……Page 493
Neutropenia……Page 494
Altered platelet numbers and function……Page 495
Occurrence and frequency……Page 496
Management……Page 497
Immunologic……Page 498
Reactions specific to side chains……Page 499
Incidence……Page 500
Patient-related factors……Page 501
Drug resistance……Page 502
Teratogenicity……Page 503
Oral contraceptive steroids……Page 504
Food-Drug Interactions……Page 505
References……Page 506
Mechanism……Page 516
References……Page 517
Biguanides+meglitinides……Page 520
Metabolism……Page 521
Mechanism and susceptibility factors……Page 522
Hematologic……Page 523
Age……Page 524
NSAIDs……Page 525
References……Page 526
References……Page 529
References……Page 531
Nervous system……Page 532
Musculoskeletal……Page 533
References……Page 534
Placebo-controlled studies……Page 536
Endocrine……Page 537
Age……Page 538
References……Page 539
Drug administration route……Page 541
References……Page 542
Use of autologous blood transfusion……Page 543
Cord blood……Page 544
Leukodepleted blood products……Page 545
Acute post-transfusion hemolytic reactions……Page 546
Reactions due to passive transfer of allo-antibodies……Page 547
Reactions to leukocytes……Page 548
Spirochetes……Page 549
Viruses……Page 550
Other Environmental Interactions……Page 552
References……Page 553
References……Page 558
Immunologic……Page 559
References……Page 560
References……Page 561
References……Page 562
References……Page 563
Drug formulations……Page 565
References……Page 566
Adverse effects……Page 567
References……Page 568
References……Page 569
References……Page 570
References……Page 571
Nervous system……Page 572
Immunologic……Page 573
References……Page 574
Reproductive system……Page 577
References……Page 578
Reference……Page 579
Nervous system……Page 581
Calcium channel blockers……Page 582
References……Page 583
Drug dependence……Page 585
Drug dosage regimens……Page 586
References……Page 587
Itraconazole……Page 589
References……Page 590
Reproductive system……Page 592
References……Page 593
References……Page 596
Serosae……Page 597
References……Page 598
Gastrointestinal……Page 599
Tumorigenicity……Page 600
Other features of the patient……Page 601
Idrocilamide……Page 602
References……Page 603
References……Page 605
Immunologic……Page 606
References……Page 607
References……Page 608
Disturbances of cardiac rhythm……Page 609
Metabolism……Page 610
Skin……Page 611
Susceptibility Factors……Page 612
Carbamazepine……Page 613
Grapefruit juice……Page 614
References……Page 615
References……Page 621
Reference……Page 622
References……Page 623
Tolerance and dependence……Page 625
General adverse effects……Page 626
Cardiac dysrhythmias……Page 627
Psychological, psychiatric……Page 628
Cognitive effects……Page 629
Immunologic……Page 630
Barbiturates, short-acting……Page 631
References……Page 632
Reference……Page 635
Iron and other transition metals……Page 636
References……Page 637
Nervous system……Page 638
Metabolism……Page 639
Hematologic……Page 640
Immunologic……Page 641
Hepatic disease……Page 642
Antiretroviral protease inhibitors……Page 643
Olanzapine……Page 644
References……Page 645
Valproic acid……Page 649
References……Page 650
References……Page 652
Urinary tract……Page 654
Drug overdose……Page 655
References……Page 656
Cardiac dysrhythmias and heart block……Page 659
Effects of digitalis on the electrocardiogram……Page 660
Long-term use and cardiovascular adverse effects of cardiac glycosides……Page 661
Nervous system……Page 662
Metabolism……Page 663
Death……Page 664
Factors that alter the amount of digitalis that accumulates in the body or the plasma concentration at a fixed dose (pharmacokinetic factors)……Page 665
Drug administration route……Page 666
Correct electrolyte disturbances……Page 667
Give antidigoxin antibody……Page 668
Absorption……Page 669
Voglibose……Page 670
Diltiazem……Page 671
Hydralazine……Page 672
Digoxin……Page 673
St. John’s wort (Hypericum perforatum)……Page 674
Digoxin radioimmunoassays……Page 675
Diagnosis of toxicity……Page 676
References……Page 677
References……Page 685
References……Page 686
References……Page 687
Cardiovascular……Page 688
Infection risk……Page 689
Total parenteral nutrition……Page 690
References……Page 691
Fetotoxicity……Page 693
References……Page 694
Skin……Page 696
References……Page 697
References……Page 698
Hematologic……Page 699
Mechanism……Page 700
Pseudolymphoma……Page 701
Urinary tract……Page 702
Type I reactions……Page 703
Type III reactions……Page 704
Jaffee Test……Page 705
References……Page 706
References……Page 713
Chenopodium ambrosioides……Page 715
References……Page 716
Hematologic……Page 717
Aplastic anemia……Page 718
Drug tolerance……Page 719
Cytochrome P450……Page 720
References……Page 721
References……Page 724
Eyes……Page 725
Serosae……Page 726
Application to the skin……Page 727
Impregnated intravenous catheters……Page 728
References……Page 729
References……Page 731
References……Page 732
Nervous system……Page 733
Retinopathy……Page 734
Electrolyte balance……Page 735
Skin……Page 736
Drug formulations……Page 737
Digoxin……Page 738
References……Page 739
References……Page 741
References……Page 742
References……Page 743
References……Page 744
Reference……Page 745
References……Page 746
Skin……Page 748
References……Page 749
References……Page 750
Drug overdose……Page 751
References……Page 752
Nervous system……Page 754
Sensory systems……Page 756
Hyperuricemia……Page 757
Mouth and teeth……Page 758
Acute renal impairment……Page 759
Chronic renal insufficiency……Page 760
Pathophysiology……Page 761
Skin……Page 762
Musculoskeletal……Page 763
Tumorigenicity……Page 764
Lactation……Page 765
Drug overdose……Page 766
Clindamycin……Page 767
Pharmacokinetic interactions……Page 768
Macrolide antibiotics……Page 769
Orlistat……Page 770
Troglitazone……Page 771
References……Page 772
Urinary tract……Page 781
References……Page 782
References……Page 784
Urinary tract……Page 785
General……Page 786
References……Page 787
References……Page 791
Immunologic……Page 792
References……Page 793
Arthropathy……Page 794
Didanosine……Page 795
References……Page 796
Gastrointestinal……Page 800
Digoxin……Page 801
References……Page 802
Drug withdrawal……Page 805
Digoxin……Page 806
References……Page 807
References……Page 808
Gastrointestinal……Page 810
Disulfiram……Page 811
Tacrolimus……Page 812
References……Page 813
Reference……Page 816
Drug withdrawal……Page 817
References……Page 818
References……Page 819
Reference……Page 820
References……Page 821
References……Page 823
References……Page 825
References……Page 826
Drug withdrawal……Page 828
Mirtazapine……Page 829
References……Page 830
References……Page 832
Reference……Page 833
Cardiomyopathy……Page 834
Venous thromboembolism……Page 835
Parkinsonism……Page 836
Tardive tremor……Page 837
Diabetes mellitus……Page 838
Mechanism……Page 839
Monitoring therapy……Page 840
Gastrointestinal……Page 841
Sexual function……Page 842
Drug overdose……Page 843
Perphenazine……Page 844
Sertraline……Page 845
References……Page 846
Psychiatric……Page 852
Drug interactions……Page 853
References……Page 854
Drug contamination……Page 856
References……Page 857
References……Page 858
General adverse effects……Page 859
Symptoms of cardiac ischemia……Page 860
Other vascular disease……Page 861
Cardiovascular effects of cocaine as a local anesthetic……Page 862
Respiratory……Page 863
Ear, nose, throat……Page 864
Migraine……Page 865
Stroke……Page 866
Sensory systems……Page 867
Obsessive-compulsive disorder……Page 868
Esophageal damage……Page 869
Urinary tract……Page 870
Immunologic……Page 871
Death……Page 872
Pregnancy……Page 873
Cardiovascular……Page 874
Cognitive effects……Page 875
Fetotoxicity……Page 877
Nervous system……Page 879
Drug overdose……Page 880
Alcohol……Page 881
References……Page 882
Pancreas……Page 890
Drug dependence……Page 891
References……Page 892
References……Page 894
Immunologic……Page 895
References……Page 896
General adverse effects……Page 897
Acupuncture……Page 898
Infection risk……Page 900
Trauma……Page 901
Homeopathy……Page 902
Cardiovascular……Page 903
Nervous system……Page 904
References……Page 905
Reference……Page 910
Copper-containing intrauterine contraceptive devices……Page 912
Liver……Page 913
References……Page 914
References……Page 916
Uses……Page 917
Therapeutic studies……Page 918
General adverse effects……Page 919
Cardiomyopathy……Page 920
Respiratory……Page 921
Nervous system……Page 922
Frequency……Page 923
Psychological, psychiatric……Page 924
Memory……Page 925
Psychoses……Page 926
Pituitary-adrenal axis……Page 927
Lipid metabolism……Page 928
Leukocytes……Page 929
Ischemic colitis……Page 930
Pancreas……Page 931
Contact allergy……Page 932
Presentation……Page 934
Mechanisms……Page 935
Comparisons of glucocorticoids……Page 936
Calcium and vitamin D……Page 937
Bisphosphonates……Page 938
Avascular necrosis……Page 939
Growth in children……Page 940
Immunologic……Page 941
Class I immune reactions……Page 942
Bacterial infections……Page 943
Fungal and yeast infections……Page 944
Tumorigenicity……Page 945
Endocrine……Page 946
Teratogenicity……Page 947
Fetotoxicity……Page 948
Elderly people……Page 949
Pulse or megadose therapy……Page 950
Sensory systems……Page 951
Nervous system……Page 952
Intrathecal……Page 953
Intra-articular and periarticular administration……Page 954
Rectal administration……Page 955
Calcium channel blockers……Page 956
References……Page 957
Inhalation devices……Page 971
Cataract……Page 972
Adrenal suppression by inhaled glucocorticoids in children……Page 973
Metabolism……Page 975
Contact allergy……Page 976
Effects on bone mineral density……Page 977
Effects on bone mineral density in children……Page 978
Dose relation……Page 979
Time course……Page 980
Prevention of osteoporosis with bisphosphonates……Page 981
Growth……Page 982
Reversibility……Page 983
References……Page 984
References……Page 989
Fluid balance……Page 991
Pregnancy……Page 992
References……Page 993
Dose-dependency……Page 995
Skin necrosis……Page 996
Musculoskeletal……Page 997
Teratogenicity……Page 998
Other features of the patient……Page 999
Methylprednisolone……Page 1000
Miconazole……Page 1003
References……Page 1004
Prothrombotic effects……Page 1012
Respiratory……Page 1014
Gastric damage……Page 1015
Kidneys……Page 1019
Reproductive system……Page 1020
Sulfonamide-like allergic adverse reactions……Page 1021
References……Page 1022
References……Page 1027
Liver……Page 1028
References……Page 1029
References……Page 1032
Reference……Page 1033
Reference……Page 1034
References……Page 1035
Endocrine……Page 1036
Urinary tract……Page 1037
Infection risk……Page 1038
Other tumors……Page 1039
Teratogenicity……Page 1040
References……Page 1041
References……Page 1044
References……Page 1045
References……Page 1046
Extravasation from a central venous catheter……Page 1047
Hematologic……Page 1048
Gastrointestinal……Page 1049
Tumorigenicity……Page 1050
Risks in transplant recipients……Page 1051
References……Page 1052
General Information……Page 1056
References……Page 1057
References……Page 1058
Immunologic……Page 1060
References……Page 1061
References……Page 1063
Observational studies……Page 1064
Liver……Page 1065
References……Page 1066
Respiratory……Page 1068
Eyes……Page 1069
Mineral balance……Page 1070
Bone dysplasia……Page 1071
Presentation……Page 1072
Mucormycosis……Page 1073
Other features of the patient……Page 1074
References……Page 1075
References……Page 1081
Rocuronium……Page 1082
References……Page 1083
References……Page 1084
Fluid balance……Page 1086
Chlorpromazine……Page 1087
References……Page 1088
Reference……Page 1090
Reference……Page 1091
Urinary tract……Page 1092
Prevention……Page 1094
Drug administration route……Page 1095
References……Page 1096
Psychological, psychiatric……Page 1098
Drug formulations……Page 1099
References……Page 1100
References……Page 1102
Serosae……Page 1104
References……Page 1105
Progressive spongiform leukoencephalopathy……Page 1106
Musculoskeletal……Page 1108
Fetotoxicity……Page 1109
Alcohol……Page 1110
References……Page 1111
Skin……Page 1113
Drug overdose……Page 1114
Naltrexone……Page 1115
References……Page 1116
References……Page 1118
Skin……Page 1119
Triamterene……Page 1120
References……Page 1121
References……Page 1123
Reference……Page 1124
Wolbachia……Page 1125
References……Page 1126
History……Page 1129
Vaginal adenosis and adenocarcinoma……Page 1130
References……Page 1131
Reference……Page 1134
General Information……Page 1135
Ciclosporin……Page 1136
Lovastatin……Page 1137
References……Page 1138
References……Page 1140
References……Page 1141
References……Page 1142
Reference……Page 1143
Prolintane……Page 1144
References……Page 1145
Reference……Page 1146
Nervous system……Page 1147
References……Page 1148
References……Page 1150
References……Page 1152
References……Page 1153
References……Page 1154
Other features of the patient……Page 1155
References……Page 1156
Psychological, psychiatric……Page 1158
Benzodiazepines……Page 1159
References……Page 1160
Adverse effects……Page 1162
Thiazide and loop diuretics……Page 1163
Aldosterone receptor antagonists……Page 1164
Metabolism……Page 1165
Hyperuricemia……Page 1166
Hyponatremia……Page 1167
Susceptibility factors……Page 1168
Mineral balance……Page 1169
Sexual function……Page 1170
Tumorigenicity……Page 1171
Pregnancy……Page 1172
Cardiac glycosides……Page 1173
References……Page 1174
Cardiac dysrhythmias……Page 1179
References……Page 1180
Amiodarone……Page 1183
Cardiovascular……Page 1184
References……Page 1185
References……Page 1188
Urinary tract……Page 1190
References……Page 1191
References……Page 1195
References……Page 1196
References……Page 1198
References……Page 1199
Methotrexate……Page 1200
References……Page 1201
References……Page 1202
Reference……Page 1203
References……Page 1204
Amphotericin……Page 1205
Enzyme inducers……Page 1206
References……Page 1207
Phenylmercuric preservatives……Page 1208
References……Page 1209
References……Page 1211
Teratogenicity……Page 1212
References……Page 1213
Hair……Page 1215
References……Page 1216
Liver……Page 1218
References……Page 1219
References……Page 1221
References……Page 1224
References……Page 1227
Myocardial ischemia……Page 1229
Gastrointestinal……Page 1230
Amfebutamone……Page 1231
SSRIs……Page 1232
References……Page 1233
Hematologic……Page 1235
References……Page 1236
Cardiovascular……Page 1237
Skin……Page 1239
Ritonavir……Page 1240
References……Page 1241
References……Page 1243
Liver……Page 1245
Carbamazepine……Page 1246
Theophylline and other xanthines……Page 1247
References……Page 1248
Hypertension……Page 1251
Vascular disease……Page 1252
Leukocytes……Page 1253
Immunologic……Page 1254
Moxifloxacin……Page 1255
References……Page 1256
References……Page 1260
Estrogenic effects of non-estrogens……Page 1261
Fluid balance……Page 1262
Liver……Page 1263
Reproductive system……Page 1264
Oral contraceptives, estrogens, and benign liver tumors……Page 1265
Hormonal replacement therapy and endometrial carcinoma……Page 1266
Oral contraceptives, cervical neoplasms, and adenosis……Page 1268
Hormone replacement therapy……Page 1269
Oral contraceptives……Page 1270
Hormone replacement therapy……Page 1272
Fertility……Page 1273
Sex……Page 1274
Transdermal patches……Page 1275
References……Page 1276
Lithium……Page 1282
References……Page 1283
References……Page 1285
Metabolism……Page 1286
Infection risk……Page 1287
References……Page 1288
Liver……Page 1290
References……Page 1291
References……Page 1293
General adverse effects……Page 1294
Coagulation……Page 1295
Urinary tract……Page 1296
Skin……Page 1298
Immunologic……Page 1299
References……Page 1300
References……Page 1303
Hematologic……Page 1304
Tumorigenicity……Page 1305
References……Page 1306
References……Page 1308
References……Page 1309
References……Page 1310
References……Page 1312
References……Page 1313
Systemic effects of ophthalmic medications……Page 1314
References……Page 1315
References……Page 1316
Lactation……Page 1317
Glycyrrhiza glabra……Page 1319
Adverse effects……Page 1320
Trifolium pratense……Page 1321
References……Page 1322
Immunologic……Page 1324
References……Page 1325
Frequency……Page 1326
Management……Page 1327
References……Page 1328
General Information……Page 1331
References……Page 1332
References……Page 1333
References……Page 1334
Clonazepam……Page 1335
References……Page 1336
References……Page 1337
References……Page 1338
Valvulopathy……Page 1339
Prevalence……Page 1340
Diagnosis……Page 1342
Effects of withdrawal of therapy on valvulopathy……Page 1343
Incidence……Page 1344
Nervous system……Page 1345
Drug abuse……Page 1346
References……Page 1347
References……Page 1351
Reference……Page 1352
Pregnancy……Page 1353
Bupivacaine, clonidine……Page 1354
Drug dosage regimens……Page 1355
Transdermal……Page 1356
Epidural……Page 1357
Bupivacaine……Page 1358
Ropivacaine……Page 1359
References……Page 1360
References……Page 1363
References……Page 1364
Musculoskeletal……Page 1365
Statins……Page 1366
References……Page 1367
References……Page 1369
References……Page 1371
Cardiac dysrhythmias……Page 1377
Urinary tract……Page 1378
Beta-adrenoceptor antagonists……Page 1379
References……Page 1380
References……Page 1382
References……Page 1383
Cardiovascular……Page 1384
Hematologic……Page 1385
Teratogenicity……Page 1386
Amphotericin……Page 1387
Clarithromycin……Page 1388
Oral contraceptives……Page 1389
Tacrolimus……Page 1390
References……Page 1391
Hematologic……Page 1395
References……Page 1396
References……Page 1398
References……Page 1399
Musculoskeletal……Page 1401
References……Page 1402
Pharmacoeconomics……Page 1403
Seizures……Page 1404
Photosensitivity……Page 1405
Immunologic……Page 1406
Teratogenicity……Page 1407
Furosemide……Page 1408
References……Page 1409
Mechanisms and pathophysiology……Page 1414
Nervous system……Page 1415
Metabolism……Page 1416
Liver……Page 1417
Skin……Page 1418
Genetic factors……Page 1419
Drug administration route……Page 1420
Pyridoxine……Page 1421
References……Page 1422
Psychological, psychiatric……Page 1426
Immunologic……Page 1427
Risperidone……Page 1428
References……Page 1429
References……Page 1431
References……Page 1432
Skin……Page 1433
References……Page 1434
References……Page 1435
Skin……Page 1436
Tolbutamide……Page 1437
References……Page 1438
Does folic acid mask vitamin B12 deficiency?……Page 1439
Hematologic……Page 1440
References……Page 1441
References……Page 1443
References……Page 1444
Biliary tract……Page 1446
Tumorigenicity……Page 1447
References……Page 1448
Terbutaline……Page 1450
Drug tolerance……Page 1451
References……Page 1452
References……Page 1454
References……Page 1455
Reference……Page 1457
Genetic factors……Page 1458
References……Page 1459
References……Page 1460
Gastrointestinal……Page 1461
Immunologic……Page 1462
ACE inhibitors……Page 1463
Vancomycin……Page 1464
References……Page 1465
References……Page 1467
Nervous system……Page 1469
Psychological, psychiatric……Page 1470
Urinary tract……Page 1471
References……Page 1472
Comparative studies……Page 1474
Gadobutrol……Page 1475
Uses of gadolinium other than in MRI scanning……Page 1476
Urinary tract……Page 1477
Drug administration route……Page 1478
References……Page 1479
References……Page 1481
References……Page 1482
Hematologic……Page 1484
References……Page 1485
References……Page 1487
References……Page 1489
References……Page 1491
References……Page 1492
References……Page 1493
Isoflurane+nitrous oxide versus propofol……Page 1494
Propofol versus sevoflurane……Page 1495
Cardiovascular……Page 1496
Nervous system……Page 1497
Urinary tract……Page 1498
Immunologic……Page 1499
Mutagenicity……Page 1500
References……Page 1501
Urinary tract……Page 1505
Drug dosage regimens……Page 1506
Monitoring Therapy……Page 1507
References……Page 1508
References……Page 1510
References……Page 1511
References……Page 1512
References……Page 1515
References……Page 1516
Immunologic……Page 1517
References……Page 1518
References……Page 1519
References……Page 1520
Polyethylene glycol……Page 1521
Drug formulations……Page 1522
References……Page 1523
Metallic gold……Page 1525
Nervous system……Page 1526
Hematologic……Page 1527
Liver……Page 1528
Skin……Page 1529
Infection risk……Page 1530
References……Page 1531
Sensory systems……Page 1534
Musculoskeletal……Page 1535
Tumorigenicity……Page 1536
References……Page 1537
Reproductive system……Page 1541
Malignant melanoma……Page 1542
Ovarian cancer……Page 1543
References……Page 1544
Use in healthy volunteers……Page 1546
Pulmonary toxicity in patients receiving chemotherapy……Page 1547
Sensory systems……Page 1548
Hemopoietic tissues……Page 1549
Neutrophilic dermatitis……Page 1550
Type I reactions……Page 1551
G-CSF-induced leukemia and myelodysplasia in patients with aplastic anemia or congenital neutropenia……Page 1552
Blood glucose analysis……Page 1553
References……Page 1554
Clotting factors……Page 1558
Vasculitis……Page 1559
Theophylline……Page 1560
References……Page 1561
References……Page 1563
Pregnancy……Page 1564
References……Page 1565
References……Page 1567
References……Page 1568
Diltiazem……Page 1372
Recombinant DNA technology using Vaccinia virus……Page 1373
Ears……Page 1374
General Information……Page 1570
Regimens using different conjugated vaccines for primary series……Page 1571
References……Page 1572
References……Page 1574
Grapefruit juice……Page 1575
References……Page 1576
References……Page 1577
Nervous system……Page 1578
Sexual function……Page 1579
Valproate……Page 1580
References……Page 1581
Incidence……Page 1583
Body temperature……Page 1584
References……Page 1585
References……Page 1588
Thrombin and thromboplastin……Page 1590
References……Page 1591
Hemorrhage……Page 1592
Thrombocytopenia……Page 1593
Presentation……Page 1594
Skin necrosis……Page 1595
Pregnancy……Page 1596
Propranolol……Page 1597
References……Page 1598
Surveillance of hepatitis B adverse events in the USA and Australia……Page 1602
General adverse effects……Page 1603
Multiple sclerosis……Page 1604
Skin……Page 1606
Drug dosage regimens……Page 1607
References……Page 1608
General adverse effects……Page 1611
Quality control and purity of herbal products……Page 1612
Adulteration with allopathic drugs……Page 1613
Adulteration with heavy metals……Page 1614
Copaltra……Page 1615
Kampo medicines……Page 1616
Monographs on herbal products……Page 1617
References……Page 1622
References……Page 1627
Drug overdose……Page 1628
References……Page 1629
Reference……Page 1630
Musculoskeletal……Page 1631
References……Page 1632
Musculoskeletal……Page 1634
Tumorigenicity……Page 1635
Coumarin anticoagulants……Page 1636
Troglitazone……Page 1637
References……Page 1638
Pregnancy……Page 1641
References……Page 1642
References……Page 1643
References……Page 1644
Overall benefit-to-harm balance of combined oral contraceptives……Page 1645
History……Page 1646
Effects of dosage and formulation……Page 1647
Age……Page 1648
Mechanisms……Page 1649
Third-generation oral contraceptives and thromboembolism……Page 1650
The third-generation oral contraceptives: a judicial assessment……Page 1652
Arterial complications……Page 1653
Estrogens versus progestogens……Page 1654
Hypertension……Page 1655
Nervous system……Page 1656
Lipid metabolism……Page 1657
Vitamin C……Page 1658
Hematologic……Page 1659
Liver……Page 1660
Skin……Page 1661
Breasts……Page 1662
Uterus……Page 1663
Drug abuse……Page 1664
Congenital anomalies……Page 1665
Relative contraindications……Page 1666
Interactions in which other drugs influence the effects of contraceptive steroids……Page 1667
Benzodiazepines……Page 1668
Griseofulvin……Page 1669
Smoking……Page 1670
References……Page 1671
Acceptability……Page 1680
Reproductive system……Page 1681
Drug formulations……Page 1682
References……Page 1683
References……Page 1685
References……Page 1686
Weight……Page 1688
Musculoskeletal……Page 1689
Age……Page 1690
Dexamfetamine……Page 1691
References……Page 1692
Benefit to harm balance……Page 1694
Metabolism……Page 1695
Reproductive system……Page 1696
Drug formulations……Page 1697
References……Page 1698
References……Page 1700
References……Page 1701
References……Page 1703
References……Page 1704
References……Page 1705
References……Page 1707
References……Page 1708
Hematologic……Page 1709
Other features of the patient……Page 1710
References……Page 1711
References……Page 1713
References……Page 1714
References……Page 1715
References……Page 1716
References……Page 1718
Polyclonal antilymphocyte immunoglobulins……Page 1719
Aseptic meningitis……Page 1720
Leukocytes……Page 1721
Skin……Page 1722
Autoimmune disease……Page 1723
Intravenous……Page 1724
References……Page 1725
Risk management……Page 1730
Insect venoms……Page 1731
References……Page 1732
References……Page 1733
Hair……Page 1735
Sildenafil……Page 1736
References……Page 1737
Fluid balance……Page 1739
Sexual function……Page 1740
Elderly people……Page 1741
Beta-blockers……Page 1742
References……Page 1743
References……Page 1746
Autoantibodies and autoimmunity……Page 1747
Immediate hypersensitivity reactions……Page 1748
Bacterial infections……Page 1749
References……Page 1750
Incidence……Page 1753
Guillain-Barré syndrome……Page 1754
Anticonvulsants……Page 1755
References……Page 1756
Beta2-adrenoceptor agonists……Page 1758
References……Page 1759
General adverse effects……Page 1761
Frequency……Page 1762
Presentation……Page 1763
Susceptibility factors……Page 1765
Fat metabolism……Page 1766
Immunologic……Page 1767
Pathogenesis……Page 1768
Drug tolerance……Page 1769
Insulin pens……Page 1770
Efficacy……Page 1771
Local adverse effects……Page 1772
Suitable types of insulin……Page 1773
Drug overdose……Page 1774
Blood glucose measurement……Page 1775
References……Page 1776
References……Page 1783
References……Page 1785
References……Page 1786
Comparative studies……Page 1788
Renal disease……Page 1789
References……Page 1790
General adverse effects……Page 1792
Cardiac complications……Page 1793
Respiratory……Page 1794
Demyelination……Page 1795
Seizures……Page 1796
Ears……Page 1797
Presentation……Page 1798
Susceptibility factors……Page 1799
Management……Page 1800
Time-course……Page 1801
Susceptibility factors……Page 1802
Mechanisms……Page 1803
Susceptibility factors……Page 1804
Platelet aggregation……Page 1805
Exacerbation of chronic viral hepatitis……Page 1806
Pancreas……Page 1807
Urinary tract……Page 1808
Vitiligo……Page 1809
Musculoskeletal……Page 1810
Interferon alfa antibodies……Page 1811
Autoimmune disorders……Page 1812
Systemic lupus erythematosus and rheumatoid arthritis……Page 1813
Immunosuppressive effects……Page 1814
Age……Page 1815
Erythropoietin……Page 1816
References……Page 1817
Psychological, psychiatric……Page 1831
Liver……Page 1832
Musculoskeletal……Page 1833
Teratogenicity……Page 1834
References……Page 1835
General Information……Page 1837
Immunologic……Page 1838
References……Page 1839
General adverse effects……Page 1840
References……Page 1841
Placebo-controlled studies……Page 1842
Angiotensin-converting enzyme (ACE) inhibitors……Page 1843
References……Page 1844
References……Page 1845
References……Page 1846
General Information……Page 1847
General adverse effects……Page 1848
Incidence……Page 1849
Delayed reactions……Page 1850
Prevention and management……Page 1852
Cost to benefit ratio……Page 1853
Effects on blood pressure……Page 1854
Electrocardiographic effects……Page 1855
Respiratory……Page 1856
Nervous system……Page 1857
Convulsions……Page 1859
Paraplegia……Page 1860
Psychological, psychiatric……Page 1861
Endocrine……Page 1862
Hematologic……Page 1863
Mouth and teeth……Page 1864
Liver……Page 1865
Presentation……Page 1866
Placebo-controlled studies……Page 1867
Pathophysiology……Page 1868
Acetylcysteine……Page 1870
Calcium channel blockers……Page 1871
Theophylline……Page 1872
Skin……Page 1873
Non-IgE-mediated anaphylactic (anaphylactoid) reactions……Page 1875
Prevention……Page 1876
Age……Page 1877
Drug formulations……Page 1878
Oral and rectal……Page 1879
Intravenous injection……Page 1880
Bronchography……Page 1881
Hysterosalpingography……Page 1882
Oily media……Page 1883
Urography……Page 1884
Metformin……Page 1885
References……Page 1886
General adverse effects……Page 1896
Endocrine……Page 1897
Immunologic……Page 1898
References……Page 1899
References……Page 1902
References……Page 1904
Salmeterol……Page 1905
References……Page 1906
References……Page 1908
References……Page 1909
References……Page 1910
Parenteral iron……Page 1911
Topical iron……Page 1912
Gastrointestinal……Page 1913
Skin……Page 1914
Intramuscular iron……Page 1915
Renal disease……Page 1916
Oral iron……Page 1917
References……Page 1918
Reference……Page 1921
Suxamethonium……Page 1922
References……Page 1923
Psychological, psychiatric……Page 1924
Pancreas……Page 1925
Mutagenicity……Page 1926
Monoamine oxidase inhibitors……Page 1927
References……Page 1928
References……Page 1930
Reference……Page 1931
Reference……Page 1932
Amphotericin……Page 1933
General adverse effects……Page 1934
Liver……Page 1935
Age……Page 1936
Benzodiazepines……Page 1937
Fentanyl……Page 1938
Methylprednisolone……Page 1939
Ropivacaine……Page 1940
Simvastatin……Page 1941
References……Page 1942
Sarcoptes scabiei……Page 1947
Sarcoptes scabiei……Page 1948
Onchocerciasis……Page 1949
Loa loa encephalopathy……Page 1950
Hematologic……Page 1951
References……Page 1952
Reference……Page 1954
Nervous system……Page 1955
References……Page 1956
References……Page 1957
References……Page 1958
Psychotomimetic effects……Page 1960
Drug administration route……Page 1961
References……Page 1962
Endocrine……Page 1964
Skin……Page 1965
Antihistamines……Page 1966
HIV protease inhibitors……Page 1967
Theophylline……Page 1968
References……Page 1969
References……Page 1973
References……Page 1974
References……Page 1975
Fetotoxicity……Page 1977
References……Page 1978
Teucrium species……Page 1979
Observational studies……Page 1982
Comparative studies……Page 1983
Worsening seizures……Page 1984
Hematologic……Page 1985
Skin……Page 1986
Hair, nails, sweat glands……Page 1987
Drug withdrawal……Page 1988
Drug overdose……Page 1989
Rifampicin……Page 1990
References……Page 1991
Corneal damage……Page 1994
Optic disc and macular edema……Page 1995
Eyelashes……Page 1996
Cinnamonum camphora……Page 1998
References……Page 1999
Stimulant laxatives……Page 2001
Rheum palmatum (medicinal rhubarb)……Page 2002
Lactulose (rINN) and lactitol (rINN)……Page 2003
References……Page 2004
Herbal remedies……Page 2006
References……Page 2007
Respiratory……Page 2008
Liver……Page 2011
Warfarin……Page 2012
References……Page 2013
Leukotriene receptor antagonists and Churg-Strauss syndrome……Page 2017
Incidence……Page 2018
References……Page 2019
Colorectal cancer……Page 2021
Nervous system……Page 2022
Hematologic……Page 2023
Immunologic……Page 2024
Warfarin……Page 2025
References……Page 2026
Drug overdose……Page 2028
References……Page 2029
General Information……Page 2030
References……Page 2031
Dyskinesias……Page 2032
Sleep disorders……Page 2033
Endocrine……Page 2035
Teratogenicity……Page 2036
Diagnosis of Adverse Drug Reactions……Page 2037
References……Page 2038
Gastrointestinal……Page 2040
Warfarin……Page 2041
References……Page 2042
Cardiovascular……Page 2044
Nervous system……Page 2045
Hematologic……Page 2046
Fetotoxicity……Page 2047
Patches……Page 2048
Itraconazole……Page 2049
References……Page 2050
Skin……Page 2053
References……Page 2054
Hematologic……Page 2056
Skin……Page 2057
Drug resistance……Page 2058
References……Page 2059
References……Page 2062
Cardiovascular……Page 2063
References……Page 2064
Hematologic……Page 2110
Immunologic……Page 2111
Fertility……Page 2112
Cardiovascular……Page 2113
Nervous system……Page 2114
Caudal anesthesia……Page 2116
Dental anesthesia……Page 2117
Epidural anesthesia……Page 2118
Comparative studies……Page 2119
Respiratory……Page 2120
Nervous system……Page 2121
Susceptibility factors……Page 2123
Intrathecal (spinal) anesthesia……Page 2124
Cardiovascular……Page 2125
Nervous system……Page 2126
Gastrointestinal……Page 2131
Nervous system……Page 2132
Nasal anesthesia……Page 2133
Retrobulbar anesthesia……Page 2134
Peribulbar anesthesia……Page 2135
Topical anesthesia……Page 2136
Paravertebral anesthesia……Page 2137
Stellate ganglion anesthesia……Page 2138
Submucosal anesthesia……Page 2139
References……Page 2140
References……Page 2150
General Information……Page 2151
Immunologic……Page 2152
References……Page 2153
Placebo-controlled studies……Page 2155
Drug withdrawal……Page 2156
References……Page 2157
General Information……Page 2159
References……Page 2160
Teratogenicity……Page 2161
Hematologic……Page 2164
References……Page 2165
General Information……Page 2166
Musculoskeletal……Page 2167
References……Page 2169
Susceptibility Factors……Page 2170
References……Page 2171
References……Page 1980
Pharmacoeconomics……Page 2172
Gastrointestinal……Page 2173
Drug tolerance……Page 2174
Ciclosporin……Page 2175
Digoxin……Page 2176
Oral contraceptives……Page 2177
Verapamil……Page 2178
References……Page 2179
General adverse effects……Page 2185
References……Page 2186
Fertility……Page 2188
References……Page 2189
Nervous system……Page 2190
References……Page 2191
General Information……Page 2193
Drug overdose……Page 2194
References……Page 2195
General adverse effects……Page 2196
General adverse effects……Page 2197
General adverse effects……Page 2198
Encephalopathy……Page 2199
Meningitis……Page 2200
Measles-mumps-rubella……Page 2201
Gait disturbance……Page 2202
History……Page 2203
Measles-mumps-rubella……Page 2204
Measles-mumps-rubella……Page 2205
Rubella……Page 2206
Rubella……Page 2207
Measles……Page 2208
References……Page 2209
Liver……Page 2213
References……Page 2214
General adverse effects……Page 2215
Fluid balance……Page 2216
Fertility……Page 2217
References……Page 2218
References……Page 2220
Psychological, psychiatric……Page 2222
Gastrointestinal……Page 2223
Teratogenicity……Page 2224
References……Page 2225
Combinations of oral hypoglycemic drugs……Page 2228
Meglitinides+thiazolidinediones……Page 2229
Hepatic disease……Page 2230
References……Page 2231
References……Page 2233
Endocrine……Page 2234
Drug overdose……Page 2235
References……Page 2236
Gastrointestinal……Page 2237
References……Page 2238
General Information……Page 2239
Conjugated meningococcal vaccines……Page 2240
Nervous system……Page 2241
References……Page 2242
Drug overdose……Page 2243
References……Page 2244
References……Page 2245
References……Page 2247
Dental amalgam……Page 2249
Thiomersal……Page 2250
Psychological, psychiatric……Page 2252
References……Page 2253
Reference……Page 2256
Hematologic……Page 2257
References……Page 2258
Cardiovascular……Page 2259
Death……Page 2260
Drug dosage regimens……Page 2261
Fluvoxamine……Page 2262
Use of methadone in opioid withdrawal……Page 2263
References……Page 2264
General adverse effects……Page 2266
Susceptibility factors……Page 2267
Hematologic……Page 2268
Frequency……Page 2269
Susceptibility factors……Page 2270
Skin……Page 2271
Infection risk……Page 2272
Tumorigenicity……Page 2273
Glucocorticoids……Page 2274
References……Page 2275
Liver……Page 2280
References……Page 2281
Cardiovascular……Page 2282
Respiratory……Page 2283
Nervous system……Page 2284
Psychological, psychiatric……Page 2285
Cognitive effects……Page 2287
Electrolyte balance……Page 2288
Mouth and teeth……Page 2289
Liver……Page 2290
Death rate……Page 2291
Pregnancy……Page 2292
Ritonavir……Page 2293
References……Page 2294
Nervous system……Page 2297
Metabolism……Page 2298
Drug overdose……Page 2299
References……Page 2300
Immunologic……Page 2303
References……Page 2304
References……Page 2305
Ciclosporin……Page 2307
References……Page 2308
Drug abuse……Page 2309
References……Page 2310
Nervous system……Page 2311
References……Page 2312
Nervous system……Page 2313
Skin……Page 2314
Alcohol……Page 2315
References……Page 2316
Placebo-controlled studies……Page 2318
Skin……Page 2319
Sevoflurane……Page 2320
References……Page 2321
References……Page 2323
Endocrine……Page 2325
References……Page 2326
Nervous system……Page 2327
Drug withdrawal……Page 2328
Fentanyl……Page 2329
References……Page 2330
Placebo-controlled studies……Page 2333
References……Page 2334
References……Page 2336
Mouth and teeth……Page 2338
Lupus-like syndrome……Page 2339
Autoimmune hepatitis……Page 2340
References……Page 2341
Immunologic……Page 2343
References……Page 2344
Oxytocin……Page 2346
Pregnancy……Page 2347
Teratogenicity……Page 2348
References……Page 2349
References……Page 2351
General Information……Page 2353
References……Page 2354
Liver……Page 2355
Selegiline……Page 2356
References……Page 2357
References……Page 2359
General Information……Page 2360
Hypotension……Page 2361
Endocrine……Page 2362
Drug overdose……Page 2363
General……Page 2364
Ginseng……Page 2365
References……Page 2366
References……Page 2368
General adverse effects……Page 2370
References……Page 2371
References……Page 2372
Reference……Page 2374
Nausea and vomiting……Page 2375
Endocrine……Page 2376
Genetic factors……Page 2377
Drug dosage regimens……Page 2378
Droperidol……Page 2379
References……Page 2380
Liver……Page 2382
References……Page 2383
References……Page 2385
Urinary tract……Page 2387
Tumorigenicity……Page 2388
References……Page 2389
Respiratory……Page 2391
Gastrointestinal……Page 2392
Bacterial infections……Page 2393
Pregnancy……Page 2394
References……Page 2395
Myristica fragrans……Page 2397
References……Page 2398
References……Page 2399
Skin……Page 2400
Adverse effects……Page 2401
General Information……Page 2402
Reference……Page 2403
General Information……Page 2404
Musculoskeletal……Page 2405
References……Page 2406
General Information……Page 2408
Fetotoxicity……Page 2409
References……Page 2410
Gastrointestinal……Page 2411
References……Page 2412
Skin……Page 2414
References……Page 2415
Liver……Page 2417
Clozapine……Page 2418
References……Page 2419
Cannabinoids……Page 2421
References……Page 2422
Gastrointestinal……Page 2423
References……Page 2424
Effects on fertility……Page 2425
Comparisons of different typical drugs……Page 2426
Atypical versus typical drugs……Page 2427
Comparisons of different atypical drugs……Page 2433
Clozapine……Page 2434
Cardiac dysrhythmias……Page 2435
Seizures……Page 2437
Extrapyramidal effects……Page 2438
Akathisia……Page 2439
Neuroleptic malignant syndrome……Page 2445
Psychological, psychiatric……Page 2448
Cognitive effects……Page 2449
Lipid concentrations……Page 2450
Weight gain……Page 2451
Liver……Page 2453
Male dysfunction……Page 2454
Body temperature……Page 2455
Drug withdrawal……Page 2456
Children……Page 2457
Drug overdose……Page 2458
Benzodiazepines……Page 2459
Lithium……Page 2460
Thiazide diuretics……Page 2461
References……Page 2462
Mechanisms……Page 2477
Pregnancy……Page 2478
Hemodilution……Page 2479
Peptide antibiotics……Page 2480
Intravenous anesthetics……Page 2481
References……Page 2482
Liver……Page 2486
St John’s wort……Page 2487
References……Page 2488
General Information……Page 2489
Immunologic……Page 2490
References……Page 2491
Other features of the patient……Page 2493
References……Page 2494
Musculoskeletal……Page 2496
References……Page 2497
Cardiovascular……Page 2499
Liver……Page 2500
Drug formulations……Page 2501
References……Page 2502
Cardiac dysrhythmias……Page 2504
Gastrointestinal……Page 2505
Pregnancy……Page 2506
Tacrolimus……Page 2507
References……Page 2508
References……Page 2510
Liver……Page 2511
References……Page 2512
General adverse effects……Page 2513
References……Page 2514
Placebo-controlled studies……Page 2516
Cardiovascular……Page 2517
Skin……Page 2518
Tumorigenicity……Page 2519
Anal……Page 2520
Sildenafil……Page 2521
Respiratory……Page 2525
Methemoglobinemia……Page 2526
Drug withdrawal……Page 2527
References……Page 2528
Sensory systems……Page 2530
Skin……Page 2531
References……Page 2532
References……Page 2536
Nervous system……Page 2537
Teratogenicity……Page 2538
References……Page 2539
Liver……Page 2541
References……Page 2542
Meta-analyses……Page 2544
Prospective studies……Page 2545
Congestive heart failure……Page 2546
Hematologic……Page 2547
Susceptibility factors……Page 2548
Comparative studies of different NSAIDs……Page 2551
Small bowel damage……Page 2552
Large bowel damage……Page 2553
Types of complication……Page 2554
Chronic renal disease……Page 2555
Skin……Page 2556
Photosensitivity to topical NSAIDs……Page 2557
Immunologic……Page 2558
Teratogenicity……Page 2559
Alcohol……Page 2560
Antihypertensive drugs……Page 2561
References……Page 2562
Drug formulations……Page 2570
References……Page 2571
General Information……Page 2572
References……Page 2573
Mitochondrial toxicity associated with NRTIs……Page 2574
Lactic acidosis……Page 2575
References……Page 2576
Rose bengal……Page 2579
References……Page 2580
Glucocorticoids……Page 2581
References……Page 2582
Observational studies……Page 2583
Extrapyramidal effects……Page 2584
Neuroleptic malignant syndrome……Page 2585
Seizures……Page 2586
Obsessive-compulsive disorder……Page 2587
Diabetes mellitus……Page 2588
Weight gain……Page 2589
Cross-reaction with clozapine……Page 2590
Sexual function……Page 2591
Carbamazepine……Page 2592
References……Page 2593
References……Page 2598
Liver……Page 2599
Drug formulations……Page 2600
References……Page 2601
Differences between individual agents……Page 2603
Opioid agonists……Page 2605
Prevention of pruritus……Page 2606
Nervous system……Page 2607
Sexual function……Page 2608
Death……Page 2609
Opioid tolerance in neonates……Page 2610
Methadone……Page 2611
Clonidine……Page 2612
Pregnancy……Page 2613
Fetotoxicity……Page 2614
Intrathecal route……Page 2615
Epidural route……Page 2616
Urinary tract……Page 2617
General……Page 2618
References……Page 2619
Drug administration route……Page 2624
References……Page 2625
Liver……Page 2626
References……Page 2627
References……Page 2628
Placebo-controlled studies……Page 2630
Lamotrigine……Page 2631
References……Page 2632
References……Page 2633
References……Page 2634
Sensory systems……Page 2636
Reference……Page 2637
Sensory systems……Page 2638
References……Page 2639
General Information……Page 2641
References……Page 2642
Cardiovascular……Page 2644
Nervous system……Page 2645
Gastrointestinal……Page 2646
Immunologic……Page 2647
References……Page 2648
References……Page 2651
Other features of the patient……Page 2653
Radiography……Page 2654
References……Page 2655
References……Page 2657
Nervous system……Page 2658
References……Page 2659
General Information……Page 2660
Nervous system……Page 2661
Analgesic nephropathy……Page 2662
Nephropathy due to non-phenacetin-containing analgesics……Page 2663
Cause……Page 2664
Associated disorders……Page 2665
Fetotoxicity……Page 2666
Alcohol……Page 2667
Adding antidotes to oral formulations……Page 2668
Alcohol……Page 2669
Interference with Diagnostic Tests……Page 2670
References……Page 2671
References……Page 2675
Cardiovascular……Page 2679
References……Page 2680
Nervous system……Page 2682
Carbohydrates……Page 2683
Amino acids……Page 2684
Calcium……Page 2685
Copper……Page 2686
Manganese……Page 2687
Selenium……Page 2688
Histiocytosis……Page 2689
Liver……Page 2690
Mechanisms and susceptibility factors……Page 2691
Management……Page 2692
Musculoskeletal……Page 2693
Immunologic……Page 2694
Infection risk……Page 2695
Age……Page 2696
Drug formulations……Page 2697
Drug administration route……Page 2698
References……Page 2699
Hematologic……Page 2704
Methadone……Page 2705
References……Page 2706
Adverse effects……Page 2707
References……Page 2708
Drug overdose……Page 2709
References……Page 2710
General adverse effects……Page 2711
Prevention……Page 2712
Nervous system……Page 2713
Sensory systems……Page 2714
Hematologic……Page 2715
Gastrointestinal……Page 2716
Urinary tract……Page 2717
Effects on collagen and elastin……Page 2719
Elastosis perforans serpiginosa, cutis laxa, and pseudoxanthoma elasticum……Page 2720
Pemphigus……Page 2721
Reproductive system……Page 2722
ANCA-positive vasculitis……Page 2723
Lupus-like syndrome……Page 2724
Teratogenicity……Page 2725
Reporting adverse reactions……Page 2726
References……Page 2727
Electrolyte balance……Page 2738
Hematologic……Page 2739
Other penicillins……Page 2740
Presentation……Page 2741
Diagnosis……Page 2743
Desensitization……Page 2744
Lactation……Page 2745
Methotrexate……Page 2746
References……Page 2747
Pharmacokinetics……Page 2754
Respiratory……Page 2755
Skin……Page 2756
References……Page 2757
Renal disease……Page 2758
References……Page 2759
General Information……Page 2761
Sexual function……Page 2762
References……Page 2763
Acellular pertussis vaccine……Page 2764
Limb swelling after booster doses of acellular vaccines……Page 2765
Acellular pertussis vaccine versus whole-cell pertussis vaccine……Page 2766
Comparisons of DTP and DT……Page 2767
Nervous system……Page 2768
Susceptibility factors……Page 2769
References……Page 2770
Nervous system……Page 2772
Drug dosage regimens……Page 2773
References……Page 2774
Nervous system……Page 2776
References……Page 2777
Immunologic……Page 2779
References……Page 2780
General Information……Page 2781
Skin……Page 2782
References……Page 2783
Fluoxetine……Page 2785
References……Page 2786
Mutagenicity……Page 2787
References……Page 2788
Sensory systems……Page 2790
References……Page 2791
References……Page 2793
Nervous system……Page 2795
Skin……Page 2796
Tumorigenicity……Page 2797
Cyclophosphamide……Page 2798
References……Page 2799
Renal disease……Page 2802
References……Page 2803
Immunologic……Page 2804
Cutaneous carcinogenicity……Page 2805
References……Page 2806
Menstrual disturbances……Page 2808
Immunologic……Page 2809
References……Page 2810
References……Page 2812
General Information……Page 2814
References……Page 2815
General Information……Page 2816
References……Page 2817
Liver……Page 2819
References……Page 2820
Skin……Page 2821
References……Page 2822
References……Page 2823
Skin……Page 2825
References……Page 2826
References……Page 2827
Body temperature……Page 2829
References……Page 2830
General adverse effects……Page 2831
SPI-77……Page 2832
Nervous system……Page 2833
Presentation……Page 2834
Mechanism and susceptibility factors……Page 2835
Management……Page 2836
Dose-relatedness……Page 2837
Carboplatin and oxaliplatin……Page 2838
Magnesium……Page 2839
Gastrointestinal……Page 2840
Cisplatin……Page 2841
Skin……Page 2842
Immunologic……Page 2843
Drug administration route……Page 2844
Paclitaxel……Page 2845
References……Page 2846
Pneumococcal conjugated polysaccharide vaccines……Page 2854
Age……Page 2856
References……Page 2857
Reference……Page 2860
References……Page 2861
Hexavalent immunization……Page 2862
” The River “……Page 2863
Vaccine-associated poliomyelitis……Page 2864
Mechanism……Page 2865
Pregnancy……Page 2866
References……Page 2867
Immunologic……Page 2869
References……Page 2870
Respiratory……Page 2872
Drug resistance……Page 2873
References……Page 2874
Small bowel……Page 2876
Iron……Page 2877
References……Page 2878
General Information……Page 2880
Guidelines for the safe use of povidone- iodine complexes……Page 2881
Urinary tract……Page 2882
Immunologic……Page 2883
Renal disease……Page 2884
References……Page 2885
Hematologic……Page 2887
References……Page 2888
General Information……Page 2889
References……Page 2890
References……Page 2891
Nervous system……Page 2893
Drug tolerance……Page 2894
References……Page 2895
General Information……Page 2897
Hematologic……Page 2898
References……Page 2899
General Information……Page 2901
References……Page 2902
Gastrointestinal……Page 2903
References……Page 2904
Frequency……Page 2905
Presentation……Page 2906
Amiodarone……Page 2907
References……Page 2908
References……Page 2910
General Information……Page 2911
Levonorgestrel (rINN)……Page 2912
Thromboembolism and third-generation progestogens……Page 2913
Skin……Page 2914
Micronized oral formulations……Page 2915
References……Page 2916
Levothyroxine……Page 2918
References……Page 2919
Quinidine……Page 2920
Cardiovascular……Page 2921
Sexual function……Page 2922
Metoprolol……Page 2923
References……Page 2924
Propofol versus midazolam……Page 2926
Hemodynamic effects……Page 2927
Seizures……Page 2928
Lactic acidosis……Page 2929
Pancreas……Page 2930
Rhabdomyolysis and the propofol infusion syndrome……Page 2931
References……Page 2932
Immunologic……Page 2935
References……Page 2936
Raynaud’s phenomenon and digital ischemia……Page 2937
Prostaglandins in urology……Page 2938
Cardiovascular……Page 2939
Intrauterine infusion……Page 2940
References……Page 2941
Interactions between protease inhibitors……Page 2946
Combinations of NRTIs, NNRTIs, and protease inhibitors……Page 2947
Dyslipidemias……Page 2948
Pancreas……Page 2949
References……Page 2950
Nervous system……Page 2953
References……Page 2954
General adverse effects……Page 2956
References……Page 2957
Liver……Page 2960
References……Page 2961
General adverse effects……Page 2962
Skin……Page 2963
References……Page 2964
Pyrimethamine……Page 2966
Pyrimethamine+sulfadoxine……Page 2967
Pyrimethamine+sulfadoxine……Page 2968
References……Page 2969
General Information……Page 2970
References……Page 2972
References……Page 2973
See also……Page 2975
Immunologic……Page 2976
Class I antidysrhythmimc drugs……Page 2977
References……Page 2978
Eyes……Page 2981
Hematologic……Page 2982
Teratogenicity……Page 2983
Phenobarbital……Page 2984
References……Page 2985
References……Page 2987
Doses……Page 2989
Hypothyroidism……Page 2990
Tumorigenicity……Page 2991
References……Page 2992
Heparin……Page 2994
References……Page 2995
References……Page 2996
Placebo-controlled studies……Page 2998
Skin……Page 2999
References……Page 3000
References……Page 3004
Orthopedic and urological surgery……Page 3006
Nervous system……Page 3007
Drug dosage regimens……Page 3008
References……Page 3009
References……Page 3011
General Information……Page 3012
Hematologic……Page 3013
References……Page 3014
Pharmacokinetics……Page 3016
Respiratory……Page 3017
Leukocytes……Page 3018
Musculoskeletal……Page 3019
Other features of the patient……Page 3020
Ciclosporin……Page 3021
Mexiletine……Page 3022
References……Page 3023
Placebo-controlled studies……Page 3028
Observational studies……Page 3029
Extrapyramidal effects……Page 3031
Tardive dyskinesia……Page 3032
Psychological, psychiatric……Page 3033
Prolactin……Page 3034
Urinary tract……Page 3035
Lactation……Page 3036
Drug dosage regimens……Page 3037
Opioids……Page 3038
Valproate……Page 3039
References……Page 3040
Cardiovascular……Page 3045
Tumorigenicity……Page 3046
References……Page 3047
General……Page 3048
References……Page 3049
Hepatic disease……Page 3050
References……Page 3051
References……Page 3053
General Information……Page 3054
Nervous system……Page 3055
References……Page 3056
References……Page 3057
Gastrointestinal……Page 3058
References……Page 3059
Theophylline……Page 3060
References……Page 3061
References……Page 3062
Citrus paradisi (grapefruit)……Page 3063
References……Page 3064
Respiratory……Page 3066
Musculoskeletal……Page 3067
Drug formulations……Page 3068
Theophylline……Page 3069
References……Page 3070
References……Page 3071
See also……Page 3072
See also……Page 3077
References……Page 3091
See also……Page 3094
See also……Page 3104
Sensory systems……Page 3107
Calcium channel blockers……Page 3108
References……Page 3109
Skin……Page 1376
See also……Page 3131
References……Page 3146
See also……Page 3154
General Information……Page 3159
Allergens and sources……Page 3169
References……Page 3171
General Information……Page 3249
Cardiovascular……Page 3250
Nervous system……Page 3251
Diabetes mellitus……Page 3252
Liver……Page 3253
Urinary tract……Page 3254
Infection risk……Page 3255
Drug overdose……Page 3256
Protease inhibitors……Page 3257
References……Page 3258
Mechanism of action……Page 3262
Respiratory complications……Page 3263
Gastrointestinal……Page 3264
References……Page 3265
General Information……Page 3266
Nervous system……Page 3267
Ovaries……Page 3268
Tumorigenicity……Page 3269
Teratogenicity……Page 3270
References……Page 3271
References……Page 3274
General Information……Page 3275
General adverse effects……Page 3276
Urinary tract……Page 3277
Renal disease……Page 3278
References……Page 3279
Drug overdose……Page 3282
References……Page 3283
General Information……Page 3284
References……Page 3285
Leukocytes……Page 3286
Skin……Page 3287
Immunologic……Page 3288
Desipramine……Page 3289
References……Page 3290
Ketoconazole……Page 3293
References……Page 3294
Combined diphtheria+tetanus+pertussis vaccination……Page 3295
Skin……Page 3296
References……Page 3297
References……Page 3298
References……Page 3299
Periodontal disease……Page 3301
Jarisch-Herxheimer reaction……Page 3302
Bacterial resistance……Page 3303
Mouth and teeth……Page 3304
Urinary tract……Page 3305
Drug resistance……Page 3306
Coumarin anticoagulants……Page 3307
References……Page 3308
Modern uses……Page 3313
Thromboembolic disease……Page 3314
Respiratory……Page 3315
Incidence and susceptibility factors……Page 3316
Electrolyte balance……Page 3317
Skin……Page 3318
Immunologic……Page 3319
History……Page 3320
Features……Page 3321
Frequency……Page 3322
Chickens……Page 3323
Rats……Page 3324
Sedative drugs……Page 3325
References……Page 3326
General adverse effects……Page 3331
Pancreas……Page 3332
Lactation……Page 3333
Drug overdose……Page 3334
Pharmacokinetic interactions……Page 3335
Furosemide……Page 3336
Mexiletine……Page 3337
Tocainide……Page 3338
References……Page 3339
Immunologic……Page 3342
References……Page 3343
References……Page 3344
Potassium balance……Page 3346
Skin……Page 3347
Lithium……Page 3348
References……Page 3349
Combinations of oral hypoglycemic drugs……Page 3351
Respiratory……Page 3352
Troglitazone……Page 3353
Rosiglitazone……Page 3354
References……Page 3355
Allergic agranulocytosis……Page 3358
Aplastic anemia……Page 3359
Immunologic……Page 3360
Pregnancy……Page 3361
Drug dosage regimens……Page 3362
References……Page 3363
References……Page 3366
Death……Page 3368
Quinidine……Page 3369
References……Page 3370
Genetic factors……Page 3371
References……Page 3372
Hematologic……Page 3373
Immunologic……Page 3374
Streptokinase……Page 3375
References……Page 3376
General adverse effects……Page 3380
Musculoskeletal……Page 3381
Pregnancy……Page 3382
Calcium carbonate……Page 3383
References……Page 3384
Urinary tract……Page 3387
References……Page 3388
Exacerbation of seizures……Page 3389
Metabolism……Page 3390
References……Page 3391
References……Page 3393
Respiratory……Page 3394
Aplastic anemia……Page 3395
References……Page 3396
References……Page 3398
References……Page 3399
General adverse effects……Page 3400
Immunologic……Page 3401
References……Page 3402
Comparative studies……Page 3403
References……Page 3404
Tumorigenicity……Page 3405
References……Page 3406
Eyes……Page 3407
Renal disease……Page 3408
Monitoring Therapy……Page 3409
References……Page 3410
References……Page 3412
General Information……Page 3414
References……Page 3415
References……Page 3416
Placebo-controlled studies……Page 3417
Sensory systems……Page 3418
Cognitive effects……Page 3419
Metabolism……Page 3420
Body temperature……Page 3421
References……Page 3422
Irinotecan……Page 3425
Topotecan……Page 3426
Cardiovascular……Page 3427
Hematologic……Page 3428
Gastrointestinal……Page 3429
Immunologic……Page 3430
Teratogenicity……Page 3431
References……Page 3432
References……Page 3438
Bupivacaine……Page 3439
Morphine……Page 3440
Ketamine……Page 3441
Gastrointestinal……Page 3442
Oral anticoagulants……Page 3443
References……Page 3444
Sensory systems……Page 3446
References……Page 3447
Cardiovascular……Page 3450
References……Page 3451
Sexual function……Page 3452
References……Page 3453
References……Page 3455
References……Page 3457
General Information……Page 3459
Once-daily dosage……Page 3460
Direct myocardial actions……Page 3461
Hypotension……Page 3462
Respiratory……Page 3463
Anticholinergic actions……Page 3464
Serotonin syndrome……Page 3465
Mania……Page 3466
Skin……Page 3467
Fetotoxicity……Page 3468
Drug overdose……Page 3469
General……Page 3471
Fluconazole……Page 3472
Sodium valproate……Page 3473
References……Page 3474
References……Page 3479
General Information……Page 3480
Metabolism……Page 3481
Hematologic……Page 3482
Gastrointestinal……Page 3483
Fixed drug eruptions……Page 3484
Immunologic……Page 3485
Drug tolerance……Page 3486
Coumarin anticoagulants……Page 3487
Trimeprazine……Page 3488
References……Page 3489
Comparisons between triptans……Page 3495
Sensory systems……Page 3496
5-HT re-uptake inhibitors……Page 3497
References……Page 3498
References……Page 3499
References……Page 3501
Genetic factors……Page 3503
Diuretics……Page 3504
References……Page 3505
Drug administration route……Page 3507
References……Page 3508
General adverse effects……Page 3509
References……Page 3510
Galactose……Page 3511
Perflutren……Page 3512
References……Page 3513
References……Page 3515
Surveillance of adverse events following immunization……Page 3516
Terms and definitions used in surveillance programs ofadverse events and adverse effects after immunization……Page 3517
Evaluation……Page 3518
USA……Page 3519
Canada……Page 3520
Perspectives on prelicensure trials……Page 3521
Adverse events after immunization-the need for improved research, surveillance, and communication……Page 3522
Anthrax……Page 3523
Botulism……Page 3528
General adverse effects after immunization……Page 3529
Measles-mumps-rubella……Page 3530
Rabies……Page 3532
Jet-gun-associated infections……Page 3533
Sudden infant death syndrome and multiple immunizations……Page 3534
Thiomersal……Page 3535
References……Page 3536
References……Page 3540
References……Page 3542
Second-generation effects……Page 3544
Nervous system……Page 3545
Metabolism……Page 3546
Carnitine deficiency……Page 3547
Hematologic……Page 3548
Liver……Page 3549
Hair……Page 3550
Teratogenicity……Page 3551
Other features of the patient……Page 3552
Clozapine……Page 3553
References……Page 3554
Pharmacoeconomics……Page 3559
Hematologic……Page 3560
Platelets……Page 3561
Erythema multiforme……Page 3562
Sexual function……Page 3563
History……Page 3564
Reports of organisms that are resistant to vancomycin……Page 3565
Aminoglycoside antibiotics……Page 3566
Monitoring Therapy……Page 3567
References……Page 3568
Infection risk……Page 3572
References……Page 3573
References……Page 3575
Fetotoxicity……Page 3576
References……Page 3577
Psychological, psychiatric……Page 3579
Drug withdrawal……Page 3580
Monoamine oxidase inhibitors……Page 3581
References……Page 3582
Drug overdose……Page 3584
Clarithromycin……Page 3585
References……Page 3586
General Information……Page 3588
Sensory systems……Page 3589
Frequency……Page 3590
Diagnosis……Page 3591
Reversibility……Page 3592
Psychological, psychiatric……Page 3593
References……Page 3594
Vinblastine (rINN)……Page 3597
Cardiovascular……Page 3598
Peripheral neuropathy……Page 3599
Seizures……Page 3600
Gastrointestinal……Page 3601
Teratogenicity……Page 3602
References……Page 3603
General Information……Page 3607
Nervous system……Page 3608
Liver……Page 3609
Urinary tract……Page 3610
Tumorigenicity……Page 3611
Pregnancy……Page 3612
Teratogenicity……Page 3613
Ethanol……Page 3614
References……Page 3615
Acitretin……Page 3619
Retinoic acid syndrome……Page 3620
Cardiovascular……Page 3621
Nervous system……Page 3622
Taste and smell……Page 3623
Hematologic……Page 3624
Liver……Page 3625
Skin……Page 3626
Body temperature……Page 3628
Drug formulations……Page 3629
References……Page 3630
General Information……Page 3634
General adverse effects……Page 3635
Hypercalcemia……Page 3636
Urinary tract……Page 3637
Teratogenicity……Page 3638
Drug overdose……Page 3639
References……Page 3640
Acetylsalicylic acid……Page 3643
References……Page 3644
Presentation……Page 3646
Immunologic……Page 3647
Tumorigenicity……Page 3648
Drug administration route……Page 3649
References……Page 3650
References……Page 3652
Other antifungal azoles……Page 3654
References……Page 3655
References……Page 3657
References……Page 3659
References……Page 3661
References……Page 3662
Pharmacokinetics……Page 3663
Organs and Systems……Page 3664
References……Page 3665
Lactation……Page 3667
References……Page 3668
Hematologic……Page 3671
Drug overdose……Page 3672
References……Page 3673
Comparison with placebo……Page 3674
References……Page 3675
Psychological, psychiatric……Page 3677
Hepatic disease……Page 3678
References……Page 3679
Psychological, psychiatric……Page 3681
Carbamazepine……Page 3682
References……Page 3683
General Information……Page 3684
References……Page 3685
Adverse effects……Page 3686
General Information……Page 3687
References……Page 3688
Reviews
There are no reviews yet.